2023
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).
Lee S, Fan W, Wang A, Vaidya R, Redman M, Gettinger S, Bazhenova L, Herbst R, Hershman D, Unger J. Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). JCO Clinical Cancer Informatics 2023, 7: e2200165. PMID: 37084329, PMCID: PMC10281446, DOI: 10.1200/cci.22.00165.Peer-Reviewed Original ResearchConceptsSystem organ classAdverse event dataRandomized phase III trialPhase III trialsCell lung cancerOncology clinical trialsOverall toxicity profileIII trialsNeurologic toxicityTreatment armsCardiac toxicityLung cancerClinical trialsGrade 3High prevalenceOrgan classToxicity profileNivolumabTreatment groupsStage IVEndocrine toxicityType of AEToxicity typesAE termsIpilimumab
2022
2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592
Gettinger S, Schenker M, De Langen J, Fischer J, Morgensztern D, Ciuleanu T, Beck T, De Castro Carpeno J, Schumann C, Yang X, Telivala B, Deschepper K, Nadal E, Schalper K, Spires T, Balli D, Nassar A, Karam S, Bhingare A, Spigel D. 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592. Immuno-Oncology Technology 2022, 16: 100107. DOI: 10.1016/j.iotech.2022.100107.Peer-Reviewed Original Research
2019
OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer
Bazhenova L, Redman M, Gettinger S, Hirsch F, Mack P, Schwartz L, Gandara D, Bradley J, Stinchcombe T, Leighl N, Ramalingam S, Tavernier S, Minichiello K, Kelly K, Papadimitrakopoulou V, Herbst R. OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer. Journal Of Thoracic Oncology 2019, 14: s214. DOI: 10.1016/j.jtho.2019.08.423.Peer-Reviewed Original ResearchCheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC
Christoph D, Gettinger S, Beck J, Yang X, Telivala B, Morgensztern D, Velcheti V, Ramalingam S, Schalper K, Dajee M, Ranck A, Yang R, Spigel. CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. Pneumologie 2019, 73 DOI: 10.1055/s-0039-1678250.Peer-Reviewed Original Research
2018
P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012
Antonia S, Gettinger S, Borghaei H, Goldman J, Brahmer J, Ready N, Gerber D, Chow L, Juergens R, Laurie S, Shepherd F, Li X, Li A, Geese W, Hellmann M. P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012. Journal Of Thoracic Oncology 2018, 13: s458. DOI: 10.1016/j.jtho.2018.08.558.Peer-Reviewed Original Research1503TiP CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC
Gettinger S, Beck T, Yang X, Telivala B, Morgensztern D, Velcheti V, Ramalingam S, Schalper K, Dajee M, Ranck A, Yang R, Spigel D. 1503TiP CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. Annals Of Oncology 2018, 29: viii544-viii545. DOI: 10.1093/annonc/mdy292.124.Peer-Reviewed Original Research
2017
OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012
Gettinger S, Rizvi N, Chow L, Borghaei H, Brahmer J, Shepherd F, Ready N, Gerber D, Antonia S, Goldman J, Juergens R, Geese W, Young T, Li X, Hellmann M. OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012. Journal Of Thoracic Oncology 2017, 12: s250-s251. DOI: 10.1016/j.jtho.2016.11.238.Peer-Reviewed Original Research
2016
ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC Topic: Medical Oncology
Antonia S, Gettinger S, Goldman J, Brahmer J, Borghaei H, Chow L, Ready N, Gerber D, Juergens R, Shepherd F, Laurie S, Young T, Geese W, Agrawal S, Li X, Hellmann M. ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC Topic: Medical Oncology. Journal Of Thoracic Oncology 2016, 11: s250-s251. DOI: 10.1016/j.jtho.2016.09.008.Peer-Reviewed Original ResearchCheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.
Hellmann M, Gettinger S, Goldman J, Brahmer J, Borghaei H, Chow L, Ready N, Gerber D, Juergens R, Shepherd F, Laurie S, Zhou Y, Geese W, Agrawal S, Li X, Antonia S. CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. Journal Of Clinical Oncology 2016, 34: 3001-3001. DOI: 10.1200/jco.2016.34.15_suppl.3001.Peer-Reviewed Original Research
2015
3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
Hellmann M, Rizvi N, Gettinger S, Goldman J, Chow L, Juergens R, Borghaei H, Brahmer J, Shen Y, Harbison C, Nathan F, Ready N, Antonia S. 3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC). European Journal Of Cancer 2015, 51: s632-s633. DOI: 10.1016/s0959-8049(16)31738-5.Peer-Reviewed Original Research
2014
Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) Metastatic Non-Small Cell Lung Cancer
Antonia S, Gettinger S, Goldman J, Chow L, Juergens R, Borghaei H, Brahmer J, Shen Y, Harbison C, Chen A, Ready N, Rizvi N. Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) Metastatic Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s32-s33. DOI: 10.1016/j.ijrobp.2014.08.207.Peer-Reviewed Original Research